Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Phase II Clinical Trial for New Obesity Drug

08-Dec-2009 - Finland

Lightlake Therapeutics' experts have been granted ethical approval to begin selecting and gene testing subjects for a trial of a simple, safe and effective treatment for what the World Health Organisation has described as a global epidemic of unhealthy eating and obesity.

A Phase II trial for the everyday treatment against obesity and the overeating of unhealthy food, by nasal spray and a behavioural programme, will aim to prove that Lightlake's treatment can break the addictive habit of unhealthy eating, significantly reduce weight, and train the mind to embark on a healthier dietary lifestyle and sustained weight-loss.

Lightlake has been given ethical approval to begin subject selection for Phase II clinical trial under the direction of its trial coordinator Professor Hannu Eero Rafael Alho, Professor of Addiction Medicine, University of Helsinki. The Trial is being conducted in conjunction with the National Institute for Health and Welfare, in Helsinki. It will last 6 months and results are expected in the fall of 2010.

Lightlake will be initially focused on addressing one form of obesity - Binge Eating Disorder (BED). To date existing interventions from diets to drugs and surgery have failed to deliver a sustainable solution to the obesity epidemic that is resulting in the global healthcare crisis. Those products currently on the market have questions of efficacy and may come with undesirable side effects.

https://www.bionity.com/en/news/110466/lightlake-therapeutics-inc-receives-ethical-approval-to-begin-subject-selection-for-phase-ii-clinical-trial-for-new-obesity-drug.html